Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nipro Corporation
Japanese authorities have issued their first approval for a coronavirus vaccine, to Pfizer/BioNTech’s mRNA product Comirnaty, but public vaccine hesitancy and logistics challenges could be hurdles to achieving high administration rates and effective herd immunity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
- In Vitro Diagnostics
- Medical Devices
- Diagnostic Equipment & Supplies
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
- Avantec Vascular
- Goodman Company
- Nipro Medical Corporation
- Nipro North America
- Nihon Glass Shoji Co. Ltd
- Nipro ES Pharma Co., Ltd.
- Tanabe Seiyaku Hanbai Co., Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.